Biophytis SA (FR:ALBPS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis SA showcased its OBA program using BIO101 at the SCWD congress, highlighting promising results in reducing muscle loss in obese patients. The company plans to initiate a phase 2 study in 2025 to further investigate BIO101’s efficacy and safety, with results expected by the end of the year. This development is part of Biophytis’s strategic focus on advancing treatments for age-related diseases.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money